Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 10, 2010 - Issue 2
Submit an article Journal homepage
380
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer

Myra F Barginear Assistant Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, NY 10029, USA. [email protected]
&
George Raptis Director, Eva and Glenn Dubin Breast Care Center and Associate Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, NY 10029, USA
Pages 149-151 | Published online: 10 Jan 2014

References

  • Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58, 71 –96 (2008).
  • Slamon DJ. Proto-oncogenes and human cancers. N. Engl. J. Med.317, 955–957 (1987).
  • Robinson AG, Turbin D, Thomson T et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin. Breast Cancer7, 254–261 (2006).
  • Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J. Clin. Oncol.13, 2056–2065 (1995).
  • Hudis CA: Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39–51 (2007).
  • Bender LM, Nahta R: Her2 cross talk and therapeutic resistance in breast cancer. Front. Biosci.13, 3906–3912 (2008).
  • Goodman LJ, Weston JK, Lipton A. Quantitative measurement of HER3 total protein (h3t) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. J. Clin. Oncol.27(Suppl. 20), 15S (2009).
  • Burris HAVS, Rugo H, Vogel C et al. A Phase II study of trastuzumab-DM1 (t-DM1), a HER2 antibody–drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC). J. Clin. Oncol.27(Suppl. 15) (2009) (Abstract 1017).
  • Tutt A, Robson M, Garber JE et al. Phase II trial of the oral parp inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol.27, 18S (2009) (Abstract 501).
  • Tutt ARM, Garber JE, Domchek S et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol.27(Suppl. 18), (2009) (Abstract 501).
  • O’Shaughnessy J, Pippen J, Yoffe M, Patt D, Monaghan G, Bradley C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (g/c) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol.27(Suppl. 18), (2009) (Abstract 13).
  • Conlin AK, D’Andrea G, Hudis CA et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiotherapy (WBRXT). J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 1086).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.